BetaGlue Therapeutics key facts
as of Oct 2026- Developer of a medical platform designed to provide a targeted approach in the treatment of cancer.
- BetaGlue Therapeutics is valued at approximately $25.3M as of Oct 2026 (last reported valuation).
- It has raised $49.0M; the latest was Later Stage VC ($8.1M) in Apr 2025.
- Notable investors include European Innovation Council, LIFTT, NEVA SGR, Panakes Partners, Enea Tech e Biomedical — 14 tracked in total.
- Status: Privately Held (backing).
BetaGlue Therapeutics's last reported valuation, Jul 2022. Nothing priced has surfaced since.
- ·The complete investor list: 14 names
- ·Watch BetaGlue Therapeutics: the Monday email on marks, rounds and moves
BetaGlue Therapeutics funding rounds
No funding rounds for BetaGlue Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs BetaGlue Therapeutics
14+BetaGlue Therapeutics valuation
BetaGlue Therapeutics's last reported valuation was $25.3 million in Jul 2022. No priced round, secondary trade or fund mark has surfaced since.
BetaGlue Therapeutics investors
14 investors are on record for BetaGlue Therapeutics, including European Innovation Council, LIFTT, NEVA SGR and Panakes Partners.
About BetaGlue Therapeutics
Developer of a medical platform designed to provide a targeted approach in the treatment of cancer. The company offers a precision radiotherapy platform integrating radiochemistry, medical devices, and localized radiation delivery to deliver targeted treatment for solid tumor cancers, enabling oncology clinicians and healthcare providers to treat solid tumor patients with focused therapy while reducing impact on surrounding tissue.
- Sector
- Healthcare
- HQ
- Milan, Italy
- Founded
- 2009
- Employees
- 24
- Website
- betaglue.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.